Migraine, the menopause and hormone replacement therapy: A clinical review

Journal of Family Planning and Reproductive Health Care

Volumn 33, Issue 4, 2007, Pages 245-249

  MacGregor, E Anne ^a,b  

^a City of London Migraine Clinic   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIMIGRAINE AGENT; CONJUGATED ESTROGEN; CYPROTERONE ACETATE PLUS ESTRADIOL VALERATE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PROGESTERONE; TIBOLONE;

BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLIMACTERIUM; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EPISODIC TENSION HEADACHE; FLUID RETENTION; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; MEDLINE; MENOPAUSAL SYNDROME; MENOPAUSE; MIGRAINE; MIGRAINE AURA; MIGRAINE WITHOUT AURA; MOOD DISORDER; OVARIECTOMY; PATIENT COMPLIANCE; POSTMENOPAUSE; PRACTICE GUIDELINE; PROPHYLAXIS; REMISSION; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TENSION HEADACHE;

EID: 35348990262     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118907782101986     Document Type: Review

References (56)

1. Miro F, Parker SW, Aspinall LJ, Coley J, Perry PW, Ellis JE. Sequential Classification of endocrine stages during reproductive aging in women: the FREEDOM study. Menopause 2005; 12: 281-290.
2. MacGregor EA, Barnes D. Migraine in a specialist menopause clinic. Climacteric 1999; 2: 218-223.
3. Hodson J, Thompson J, al-Azzawi F. Headache at menopause and in hormone replacement therapy users. Climacteric 2000; 3: 119-124.
4. Neri I, Granella F, Nappi R, Manzoni GC, Facchinetti F, Genazzani AR. Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas 1993; 17: 31-37.
5. Mattsson P. Hormonal factors in migraine: a population-based study of women aged 40 to 74 years. Headache 2003; 43: 27-35.
6. Wang SJ, Fuh JL, Lu SR, Juang KD, Wang PH. Migraine prevalence during menopausal transition. Headache 2003; 43: 470-478.
7. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 1993; 33: 385-389.
8. Martin V, Wernke S, Mandell K, Zoma W, Bean J, Pinney S, et al. Medical oophorectomy with and without estrogen add-back therapy in the prevention of migraine headache. Headache 2003; 43: 309-321.
9. Mueller L. Predictability of exogenous hormone effect on subgroups of migraineurs. Headache 2000; 40: 189-193.
10. Aegidius KL, Zwart JA, Hagen K, Schei B, Stovner LJ. Hormone replacement therapy and headache prevalence in postmenopausal women. The Head-HUNT study. Eur J Neurol 2007; 14: 73-78.
11. Misakian AL, Langer RD, Bensenor IM, Cook NR, Manson JE, Buring JE, et al. Postmenopausal hormone therapy and migraine headache. J Womens Health (Larchmt) 2003; 12: 1027-1036.
12. Kudrow L. The relationship of headache frequency to hormone use in migraine. Headache 1975; 15: 36-40.
13. MacGregor A. Effects of oral and transdermal estrogen replacement on migraine. Cephalalgia 1999; 19: 124-125.
14. Nappi RE, Cagnacci A, Granella F, Piccinini F, Polatti F, Facchinetti F. Course of primary headaches during hormone replacement therapy. Maturitas 2001; 38: 157-163.
15. Kuhl H. Pharmacokinetics of oestrogen and progestogens. Maturitas 1990; 12: 171-197.
16. Nappi RE, Sances G, Sommacal A, Detaddei S, Facchinetti F, Cristina S, et al. Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches. Menopause 2006; 13: 818-825.
17. Kaiser HJ, Meienberg O. Deterioration of onset of migraine under oestrogen replacement therapy in the menopause. J Neurol Neurosurg Psychiatr 1993; 240: 195-197.
18. MacGregor A. Estrogen replacement and migraine aura. Headache 1999; 39: 674-678.
19. Facchinetti F, Nappi RE, Tirelli A, Polatti F, Nappi G, Sances G. Hormone supplementation differently affects migraine in postmenopausal women. Headache 2002; 42: 924-929.
20. Panay N, Studd J. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update 1997; 3: 159-171.
21. Henrich JB, Horwitz LA. A controlled study of ischemic stroke risk in migraine patients. J Clin Epidemiol 1989; 42: 773-780.
22. Tzourio C, Iglesias S, Hubert JB, Visy JM, Alperovitch A, Tehindrazanarivelo A, et al. Migraine and risk of ischaemic stroke: a case-control study. BMJ 1993; 307: 289-292.
23. Tzourio C, Tehindrazanarivelo A, Iglesias S, Alperovitch A, Chedru F, d'Anglejan-Chatillon J, et al. Case-control study of migraine and risk of ischaemic stroke in young women. BMJ 1995; 310: 830-833.
24. Carolei A, Marini C, De Matteis G. History of migraine and risk of cerebral ischaemia in young adults. The Italian National Research Council Study Group on Stroke in the Young. Lancet 1996; 347: 1503-1506.
25. Chang C, Donaghy M, Poulter N, and World Health Organisation Collaboration Study of Cardiovascular Disease and Steroid Hormone Contraception. Migraine and stroke in young women: case-control study. BMJ 1999; 318: 13-18.
26. Nightingale AL, Farmer RD. Ischemic stroke in young women: a nested case-control study using the UK General Practice Research Database. Stroke 2004; 35: 1574-1578.
27. Kurth T, Slomke MA, Kase CS, Cook NR, Lee IM, Gaziano JM, et al. Migraine, headache, and the risk of stroke in women: a prospective study. Neurology 2005; 64: 1020-1026.
28. Scher AI, Terwindt GM, Picavet HS, Verschuren WM, Ferrari MD, Launer LJ. Cardiovascular risk factors and migraine: the GEM population-based study. Neurology 2005; 64: 614-620.
29. Stang PE, Carson AP, Rose KM, Mo J, Ephross SA, Shahar E, et al. Headache, cerebrovascular symptoms, and stroke: the Atherosclerosis Risk in Communities Study. Neurology 2005; 64: 1573-1577.
30. Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener H-C, Buring JE. Migraine and risk of cardiovascular disease in women. JAMA 2006; 296: 283-291.
31. Crassard I, Conard J, Bousser MG. Migraine and haemostasis. Cephalalgia 2001; 21: 630-636.
32. Schwerzmann M, Nedeltchev K, Lagger F, Mattle HP, Windecker S, Meier B, et al. Prevalence and size of directly detected patent foramen ovale in migraine with aura. Neurology 2005; 65: 1415-1418.
33. Anzola GP, Magoni M, Guindani M, Rozzini L, Dalla Volta G. Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology 1999; 52: 1622-1625.
34. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, et al; WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289: 2673-2684.
35. Li C, Engstrom G, Hedblad B, Berglund G, Janzon L. Risk of stroke and hormone replacement therapy: a prospective cohort study. Maturitas 2005; 54: 11-18.
36. Rosano GMC, Vitale C, Fini M. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system? Ann NY Acad Sci 2006; 1092: 341-348.
37. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465-1477.
38. Board of the International Menopause Society, Pines A, Sturdee DW, Birkhauser MH, Schneider HP, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007; 10: 181-194.
39. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004; 11: 11-33.
40. Steiner TJ, Ahmed F, Findley LJ, MacGregor EA, Wilkinson M. S-Fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia 1998; 18: 283-286.
41. d'Amato CC, Pizza V, Marmolo T, Giordano E, Alfano V, Nasta A. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache 1999; 39: 716-719.
42. Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45: 144-152.
43. Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004; 107: 44-48.
44. Bickel A, Kornhuber J, Maihofner C, Ropohl A. Exacerbation of migraine attacks during treatment with the selective serotonin reuptake inhibitor sertraline. A case report. Pharmacopsychiatry 2005; 38: 327-328.
45. Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41: 119-128.
46. Burke BE, Olson RD, Cusack BJ. Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine. Biomed Pharmacother 2002; 56: 283-288.
47. Engel PA. New onset migraine associated with use of soy isoflavone supplements. Neurology 2002; 59: 1289-1290.
48. Layton D, Clarke A, Wilton LV, Shakir SA. Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study. Osteoporos Int 2005; 16: 490-500.
49. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 2003; 23: 519-527.
50. Ho JY, Chen MJ, Sheu WH, Yi YC, Tsai AC, Guu HF, et al. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Hum Reprod 2006; 21: 2715-2720.
51. White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 2006; 48: 246-253.
52. Hampton NR, Rees MC, Lowe DG, Rauramo I, Barlow D, Guillebaud J. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 2005; 20: 2653-2660.
53. Cull RE. Investigation of late-onset migraine. Scot Med J 1995; 40: 50-52.
54. Bousser MG, Conard J. TIAs, migraine and platelets. Headache 1987; 27: 522.
55. Steiner TJ, MacGregor EA, Davies PTG. Guidelines for All Healthcare Professionals in the Diagnosis and Management of Migraine, Tension-Type, Cluster and Medication-Overuse Headache (3rd edn). 2007. http://216.25.100.131/ upload/ NS_BASH/BASH_guidelines_2007.pdf [Accessed 10 June 2007].
56. Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62: 563-568.